Gilbert Halley E 4

What Happened

• Gilbert Halley E, a director of CytomX Therapeutics (CTMX), received a grant/award of 59,000 derivative shares on 2026-06-17. The filing reports $0.00 as the acquisition price (this reflects an awarded derivative security, not an open-market purchase or sale). No cash was paid as part of this reported transaction.

Key Details

• Transaction date: 2026-06-17; SEC filing date: 2026-06-22 (appears to be filed after the two-business-day Form 4 deadline).
• Transaction type: A = Grant, award or other acquisition of a derivative security (59,000 shares); price reported $0.00.
• Shares owned after transaction: not specified in the disclosed summary of this filing.
• Footnote: The award vests 100% on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting, provided Halley remains a director through the vesting date.
• No indication in the filing that shares were sold immediately or that this was a cashless exercise — it is a compensation grant.

Context

• This is a company compensation award to a director (not an open-market purchase). Such grants are common for board compensation and do not by themselves signal buying for investment purposes. The late filing may be a procedural issue; it does not change the nature of the grant but is useful to note for regulatory timeliness.